Table of Contents
Last Updated: May 13, 2022
Below is an overview of the sections found in the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.
- Overview of COVID-19
- Testing for SARS-CoV-2 Infection
- Prevention of SARS-CoV-2 Infection
- Clinical Spectrum of SARS-CoV-2 Infection
- Prioritization of Anti-SARS-CoV-2 Therapies for the Treatment and Prevention of COVID-19 When There Are Logistical or Supply Constraints
- Clinical Management Summary
- General Management of Nonhospitalized Patients With Acute COVID-19
- Therapeutic Management of Nonhospitalized Adults With COVID-19
- Therapeutic Management of Hospitalized Adults With COVID-19
- Therapeutic Management of Hospitalized Pediatric Patients With Multisystem Inflammatory Syndrome in Children (MIS-C) (With Discussion on Multisystem Inflammatory Syndrome in Adults [MIS-A])
- Care of Critically Ill Adult Patients With COVID-19 (Summary Recommendations)
- General Considerations
- Infection Control
- Hemodynamics
- Oxygenation and Ventilation
- Acute Kidney Injury and Renal Replacement Therapy
- Pharmacologic Interventions
- Extracorporeal Membrane Oxygenation
- Antiviral Drugs That Are Approved, Authorized, or Under Evaluation for the Treatment of COVID-19 (Summary Recommendations)
- Remdesivir
- Table 2a. Remdesivir: Selected Clinical Data
- Ritonavir-Boosted Nirmatrelvir (Paxlovid)
- Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications
- Molnupiravir
- Chloroquine or Hydroxychloroquine and/or Azithromycin
- Table 2b. Chloroquine or Hydroxychloroquine and/or Azithromycin: Selected Clinical Data
- Interferons
- Table 2c. Interferons: Selected Clinical Data
- Ivermectin
- Table 2d. Ivermectin: Selected Clinical Data
- Lopinavir/Ritonavir and Other HIV Protease Inhibitors
- Nitazoxanide
- Table 2e. Nitazoxanide: Selected Clinical Data
- Table 2f. Characteristics of Antiviral Agents
Anti-SARS-CoV-2 Antibody Products
- Anti-SARS-CoV-2 Antibody Products (Summary Recommendations)
- Anti-SARS-CoV-2 Monoclonal Antibodies
- Table 3a. Anti-SARS-CoV-2 Monoclonal Antibodies: Selected Clinical Data
- COVID-19 Convalescent Plasma
- Table 3b. COVID-19 Convalescent Plasma: Selected Clinical Data
- Immunoglobulins: SARS-CoV-2 Specific
- Table 3c. Characteristics of SARS-CoV-2 Antibody-Based Products
Cell-Based Therapy Under Evaluation for the Treatment of COVID-19
- Immunomodulators Under Evaluation for the Treatment of COVID-19 (Summary Recommendations)
- Colchicine
- Corticosteroids
- Table 4a. Systemic Corticosteroids: Selected Clinical Data
- Table 4b. Inhaled Corticosteroids: Selected Clinical Data
- Fluvoxamine
- Table 4c. Fluvoxamine: Selected Clinical Data
- Granulocyte-Macrophage Colony-Stimulating Factor Inhibitors
- Table 4d. Granulocyte-Macrophage Colony-Stimulating Factor Inhibitors: Selected Clinical Data
- Immunoglobulins: Non-SARS-CoV-2 Specific
- Interleukin-1 Inhibitors
- Interleukin-6 Inhibitors
- Table 4e. Interleukin-6 Inhibitors: Selected Clinical Data
- Kinase Inhibitors: Janus Kinase Inhibitors and Bruton’s Tyrosine Kinase Inhibitors
- Table 4f. Characteristics of Immunomodulators
Antithrombotic Therapy in Patients With COVID-19
- Table 5. Antithrombotic Therapy: Selected Clinical Data
- Supplements (Summary Recommendations)
- Vitamin C
- Vitamin D
- Zinc
Considerations for Using Concomitant Medications in Patients With COVID-19
- Special Considerations in Pregnancy
- Special Considerations in Children
- Special Considerations in Adults and Children With Cancer
- Special Considerations in Solid Organ Transplant, Hematopoietic Stem Cell Transplant, and Cellular Immunotherapy Candidates, Donors, and Recipients
- Special Considerations in People With HIV
- Influenza and COVID-19
Appendix A, Table 1. COVID-19 Treatment Guidelines Panel Members